# A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

> **NCT01005823** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 36 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** LEO 29102 cream
- **DRUG:** LEO 29102 placebo cream

## Key facts

- **NCT ID:** NCT01005823
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01005823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01005823, "A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01005823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*